AstraZeneca's COVID-19 Vaccine Trial Shows No Instances Of Blood Clotting

Oxford-AstraZeneca's COVID-19 vaccine has 79% efficacy at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalization, a new study finds.

The U.S.-based trial involved more than 32,000 participants and showed no instances of blood clotting, a concern that held up vaccine distribution in the European Union.

Here & Now's Callum Borchers speaks with the BBC's Nick Beake in Brussels.

This BBC interview can be heard in the Here & Now podcast or with the WBUR app.